
J&J Terminates Hep C Collaboration with Achillion
J&J’s Janssen ends a 2015 collaboration with Achillion Pharmaceuticals with a strategic decision to discontinue further development of a hepatitis C therapy in favor of pursuing hepatitis B therapeutics.
On Sep. 11, 2017, Janssen Sciences Ireland UC, a Johnson & Johnson company, and Achillion Pharmaceuticals, announced the termination of a 2015 worldwide license and collaboration arrangement under which the two companies were developing a hepatitis C treatment. Janssen said in a company press release that it had made the strategic decision to discontinue further development of JNJ-4178, an investigational hepatitis C combination regimen of three direct-acting antivirals: AL-335, odalasvir, and simeprevir.
Ongoing Phase II studies with JNJ-4178 will be completed as planned, but there will be no additional development thereafter. Janssen made this decision in light of the increasing availability of a number of highly effective therapies addressing the medical need in hepatitis C.
The companies formed the license and collaboration agreement
“Going forward, our hepatitis R&D efforts will focus on chronic hepatitis B, where a high unmet medical need still exists. Our scientists are energized by this challenge and our research ambition is to achieve a functional cure of hepatitis B which affects over a quarter of a billion people globally,” said Lawrence Blatt, PhD, global therapeutic area head, Infectious Disease Therapeutics, Janssen, in a company press release. “At Janssen, we focus our research and development on areas of greatest unmet medical need where we can combine our excellent internal science with the best available external innovation to bring optimized solutions and maximum benefit to patients.”
"We are disappointed by Janssen's decision to discontinue HCV development given the positive data presented in [Phase IIa] with JNJ-41781, demonstrating a 100% cure rate after only six weeks of therapy," stated Milind Deshpande, PhD, president and CEO of Achillion, in that company’s release. "While we believe that patients worldwide would benefit from convenient, short-duration therapies like JNJ-4178, we remain fully focused on advancing our factor D portfolio of complement alternative pathway inhibitors in areas where patient needs are greatest, and using our strong balance sheet of almost $370 million in cash and cash equivalents at June 30, 2017 to do so."
Source: Johnson & Johnson, Achillion Pharmaceuticals
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.